<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585611</url>
  </required_header>
  <id_info>
    <org_study_id>H-2005-0430</org_study_id>
    <nct_id>NCT00585611</nct_id>
  </id_info>
  <brief_title>Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients</brief_title>
  <official_title>Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to define the underlying vascular abnormalities present in patients&#xD;
      with diastolic heart failure and test the effect of a therapy aimed at vascular&#xD;
      abnormalities. This study is designed to investigate the effects of therapy with atorvastatin&#xD;
      in subjects with diastolic heart failure to improve abnormalities of vascular and myocardial&#xD;
      structure and function, with particular emphasis on arterial stiffness and endothelial&#xD;
      dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Forty subjects will be given either drug (atorvastatin 40 mg) or placebo in a randomized&#xD;
      fashion once daily for six months. Using echocardiography, tonometry, and flow mediated&#xD;
      dilation of conduit arteries and arterioles, baseline cardiovascular anatomy and physiology&#xD;
      will be defined. Subjects that enroll in the study will be required to come in for 5 study&#xD;
      visits. The initial visit is a screening visit; subject consent is obtained and an&#xD;
      echocardiogram is performed as well as blood tests. At the randomization visit (4-14 days&#xD;
      following screening), the subject will be provided with drug or placebo in a blinded&#xD;
      fashion.Also at this visit, subjects will be asked to do a 6 minute walk, QOL questionnaire,&#xD;
      and vascular function testing. There will be follow-up study visits at 1 and 3 months&#xD;
      following randomization. At each follow-up visit a medical history, pill count and brief&#xD;
      physical examination will be performed, a repeat QOL questionnaire administered, and blood&#xD;
      tests to assess safety of the statin therapy. At 6 months, the final study visit will occur.&#xD;
      At this visit a full history and detailed physical examination will be performed. Repeat&#xD;
      echocardiogram, 6 minute walk test, QOL questionnaire, and vascular function examinations&#xD;
      will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to recruit into the study&#xD;
  </why_stopped>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group</measure>
    <time_frame>6 months after initiation of intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality</measure>
    <time_frame>6 months after initiation of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test</measure>
    <time_frame>6 months after initiation of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Diastolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Heart failure patients assigned to atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin - 40 mg orally daily for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent,&#xD;
&#xD;
          -  Age &gt; 18,&#xD;
&#xD;
          -  Ejection fraction â‰¥ 50%,&#xD;
&#xD;
          -  hospitalization for heart failure in the last 6 months and&#xD;
&#xD;
          -  current NYHA Class II-IV symptoms, OR&#xD;
&#xD;
          -  current NYHA Class III-IV symptoms and one of the following:&#xD;
&#xD;
               1. ECG or echocardiographic evidence of moderate/severe left ventricular&#xD;
                  hypertrophy,&#xD;
&#xD;
               2. chest x-ray evidence of pulmonary congestion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.)&#xD;
&#xD;
          -  Prior documented LVEF &lt; 40% or qualitative moderate or greater LV systolic&#xD;
             dysfunction.&#xD;
&#xD;
          -  Current indication for statin therapy&#xD;
&#xD;
          -  Intolerance to statin therapy.&#xD;
&#xD;
          -  Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD,&#xD;
             myocardial infarction, stroke)&#xD;
&#xD;
          -  Evidence of significant myocardial ischemia on stress testing at screening visit.&#xD;
&#xD;
          -  Evidence of hepatic abnormality (defined as liver enzymes &gt; 2 times the upper limit of&#xD;
             normal values).&#xD;
&#xD;
          -  Uncontrolled hypertension (BP &gt; 150/100)&#xD;
&#xD;
          -  Significant valvular disease.&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Restrictive cardiomyopathy or systemic illness known to be associated with&#xD;
             infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis).&#xD;
&#xD;
          -  Cor pulmonale or other cause of right heart failure not related to LV dysfunction.&#xD;
&#xD;
          -  Clinically significant pulmonary disease.&#xD;
&#xD;
          -  Pericardial constriction or hemodynamically significant pleural effusion.&#xD;
&#xD;
          -  Uncontrolled arrhythmia.&#xD;
&#xD;
          -  Any systemic condition other than heart failure that may limit survival to less than 2&#xD;
             years.&#xD;
&#xD;
          -  Advance renal disease (serum creatinine &gt; 3.0 mg/dl or on dialysis)&#xD;
&#xD;
          -  Known intolerance or allergy to HMG CoA reductase inhibitors&#xD;
&#xD;
          -  Uncontrolled hyper- or hypothyroidism.&#xD;
&#xD;
          -  Any subject characteristic that may interfere with study compliance, such as baseline&#xD;
             dementia, substance abuse, history of non-compliance with medications or appointments.&#xD;
&#xD;
          -  Prisoners or other vulnerable populations.&#xD;
&#xD;
          -  Any woman of child-bearing age with a documented positive pregnancy test.&#xD;
&#xD;
          -  Subject is receiving therapy with other investigational therapy or is participating in&#xD;
             any other clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy K Sweitzer, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 3, 2008</study_first_posted>
  <results_first_submitted>March 6, 2019</results_first_submitted>
  <results_first_submitted_qc>March 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure, Congestive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>While the record documents 1 participant enrolled in this study, there are no data available to report.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin</title>
          <description>Heart failure patients assigned to atorvastatin&#xD;
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months&#xD;
placebo: placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There are no data available</population>
      <group_list>
        <group group_id="B1">
          <title>Atorvastatin</title>
          <description>Heart failure patients assigned to atorvastatin&#xD;
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Arm 2</title>
          <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months&#xD;
placebo: placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                </category>
                <category>
                  <title>Male</title>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <class_list>
            <class>
              <title>United States</title>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group</title>
        <time_frame>6 months after initiation of intervention</time_frame>
        <population>There are no data available</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Heart failure patients assigned to atorvastatin&#xD;
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carotid-femoral Pulse Wave Velocity (CFPWV) in the Statin Treated vs. Control Group</title>
          <population>There are no data available</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality</title>
        <time_frame>6 months after initiation of intervention</time_frame>
        <population>There are no data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Heart failure patients assigned to atorvastatin&#xD;
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Cardiovascular Endpoint Incorporating Quality of Life (QOL) Assessment + Hospitalizations for Cardiovascular Disease and Mortality</title>
          <population>There are no data available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test</title>
        <time_frame>6 months after initiation of intervention</time_frame>
        <population>There are no data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Heart failure patients assigned to atorvastatin&#xD;
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months&#xD;
placebo: placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Submaximal Exercise Capacity Measured by 6-minute Walk Test</title>
          <population>There are no data available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>There are no data available</time_frame>
      <desc>There are no data available to report.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin</title>
          <description>Heart failure patients assigned to atorvastatin&#xD;
Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>Atorvastatin: Atorvastatin - 40 mg orally daily for 6 months&#xD;
placebo: placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>PI left UW-Madison, has no data for participant enrolled.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Nancy Sweitzer</name_or_title>
      <organization>UW-Madison at time of study</organization>
      <email>nancysweitzer@shc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

